India's Serum Institute starts manufacturing Codagenix's potential COVID-19 vaccine


Sept 22 (Reuters) - Codagenix Inc said on Tuesday Serum Institute of India has started manufacturing the U.S. biotech firm's potential COVID-19 vaccine and it expects to begin early-stage human trial of the vaccine by the end of 2020 in the UK.

Serum Institute, the world's largest vaccine maker by number of doses produced, will develop Codagenix's CDX-005, which is delivered intranasally rather than via an injection.

Serum Institute is working on several vaccine candidates for the novel coronavirus - including potentially mass-producing the one from AstraZeneca-Oxford University that has garnered global headlines - as well as developing its own.

More than 150 potential vaccines are being developed and tested globally, with 38 in human trials, and candidates from Moderna Inc MRNA.O, Pfizer Inc PFE.N and AstraZeneca Plc AZN.L are already in late-stage trials.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

((; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.